Login / Signup

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

Taner DemirerMerih YalcinerErden AtillaRamazan İdilmanMeral Beksac
Published in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2019)
Close follow-up is recommended for not only HBsAg-positive but also HBsAg-negative patients.
Keyphrases
  • multiple myeloma
  • newly diagnosed
  • hepatitis b virus
  • end stage renal disease
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • low dose
  • patient reported outcomes
  • stem cell transplantation
  • high dose